COMMUNIQUÉS West-GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences
26/02/2026
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
26/02/2026
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
26/02/2026
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. [...]
Ryoncil® Profits Underpinning Substantial Growth Pipeline
27/02/2026
Financial Results and Operational Update for Half-Year Ended December 31, 2025 NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for [...]
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/02/2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Keros Therapeutics Appoints Charles Newton to its Board of Directors
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]
Inventiva participera à quatre conférences investisseurs en mars
26/02/2026
Daix (France), New York ( États-Unis ), le 26 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie [...]
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent [...]
Anteris Reports 2025 Financial Results and Provides Corporate Update
27/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, [...]
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
26/02/2026
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Inventiva to Participate in Four Upcoming March Investor Conferences
26/02/2026
Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral [...]
Tarsus to Participate in Upcoming Investor Conferences
26/02/2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual [...]
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
26/02/2026
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-year Achieved industry-leading 2026 AEP growth of 53% year-over-year [...]
SkinnyRx GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Program, Pricing, and FDA Regulatory Status Examined
27/02/2026
Examining SkinnyRx's Compounded GLP-1 Weight Loss Platform for 2026: Semaglutide and Tirzepatide Medication Formats, Subscription Pricing From $199 Per Month, 503A Pharmacy Sourcing, Clinical Research Boundaries, and [...]
Herz P1 Smart Ring in 2026: Features, Pricing, Accuracy Context, and What Consumers Should Verify Before Buying
27/02/2026
Examining the Herz P1 Smart Ring's Consumer Wearable Category for 2026: 24/7 Heart Rate Monitoring, Sleep Tracking, Stress and HRV Analysis, Activity Metrics, Smart Ring Pricing From $49.99 Per Unit, No Subscription [...]
Extendicare Announces 2025 Fourth Quarter and Full Year Results and Dividend Increase
26/02/2026
MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 [...]

Pages